尼古丁胺 N-甲基转移酶抑制减轻与肥胖相关的代谢功能障碍
JoAnne J Babula1, Dinh Bui1, Heather L Stevenson2
1Ridgeline Therapeutics, Houston, Texas, USA.
Diabetes, obesity & metabolism
|August 20, 2024
概括
在肥胖小鼠中,一种新型尼古丁胺胺N-甲基转移酶 (NNMT) 抑制剂,5A1MQ有效降低了体重,改善了代谢健康,并减弱了脂肪肝. 这证实了NNMT抑制作为肥胖相关代谢障碍的有前途的治疗策略.
科学领域:
- 代谢性疾病研究研究.
- 药理学 药理学是指药理学的学科.
- 肥胖研究的研究.
背景情况:
- 肥胖与代谢功能障碍和脂肪肝疾病有关.
- 尼古丁胺N-甲基转移酶 (NNMT) 参与了代谢调节.
- 针对NNMT可能为与肥胖相关的疾病提供治疗策略.
研究的目的:
- 评估NNMT抑制剂5A1MQ对饮食诱导肥胖 (DIO) 小鼠的身体组成和代谢健康的影响.
- 评估5A1MQ对脂肪肝病理和相关生物标志物的影响.
- 为了在体内描述5A1MQ的药理动力学 (PK) 和组织分布.
主要方法:
- DIO小鼠每天接受载体或5A1MQ治疗,持续28天.
- 评估了人体组成,耐葡萄糖,胰岛素敏感性和肝脏组织病理学.
- 在不同剂量路线后进行了血和组织PK研究.
主要成果:
- 5A1MQ剂量取决于降低体重和脂肪量,改善葡萄糖耐受性和增强胰岛素敏感性.
- 用5A1MQ治疗减弱肝硬化和巨细胞透,降低肝脏重量和甘油三水平.
- 5A1MQ使肝酶和体正常化,表现出改善的肝脏和代谢功能,具有良好的全身暴露和组织分布.
结论:
- 尼古丁胺N-甲基转移酶 (NNMT) 抑制是一种可行的药理方法.
- 5A1MQ有效地改善与肥胖相关的代谢失衡和肝脏病理.
- 这项研究支持NNMT抑制作为肥胖和相关代谢障碍的潜在治疗策略.
相关概念视频
01:23Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
01:23Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209